Researchers are exploring a dendritic cell-based in situ nanovaccine that aims to reprogram lipid metabolism to enhance tumor immunotherapy. This approach seeks to overcome tumor-mediated immune suppression by rewiring lipid metabolism. The treatment is being investigated as a potential frontier in cancer treatment, with a focus on its efficacy in melanoma.